GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » Operating Margin %

Translate Bio (Translate Bio) Operating Margin % : 27.88% (As of Jun. 2021)


View and export this data going back to 2018. Start your Free Trial

What is Translate Bio Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Translate Bio's Operating Income for the three months ended in Jun. 2021 was $20.3 Mil. Translate Bio's Revenue for the three months ended in Jun. 2021 was $72.6 Mil. Therefore, Translate Bio's Operating Margin % for the quarter that ended in Jun. 2021 was 27.88%.

The historical rank and industry rank for Translate Bio's Operating Margin % or its related term are showing as below:

TBIO' s Operating Margin % Range Over the Past 10 Years
Min: -5578.17   Med: -1245.48   Max: 18.52
Current: 18.52


TBIO's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -177.195 vs TBIO: 18.52

Translate Bio's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Translate Bio's Operating Income for the three months ended in Jun. 2021 was $20.3 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2021 was $41.7 Mil.


Translate Bio Operating Margin % Historical Data

The historical data trend for Translate Bio's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio Operating Margin % Chart

Translate Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
Operating Margin %
- - -5,578.17 -1,245.48 -4.86

Translate Bio Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -130.42 46.56 15.27 -50.16 27.88

Competitive Comparison of Translate Bio's Operating Margin %

For the Biotechnology subindustry, Translate Bio's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Translate Bio's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Translate Bio's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Translate Bio's Operating Margin % falls into.



Translate Bio Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Translate Bio's Operating Margin % for the fiscal year that ended in Dec. 2020 is calculated as

Operating Margin %=Operating Income (A: Dec. 2020 ) / Revenue (A: Dec. 2020 )
=-6.74 / 138.811
=-4.86 %

Translate Bio's Operating Margin % for the quarter that ended in Jun. 2021 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2021 ) / Revenue (Q: Jun. 2021 )
=20.251 / 72.649
=27.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Translate Bio  (NAS:TBIO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Translate Bio Operating Margin % Related Terms

Thank you for viewing the detailed overview of Translate Bio's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Translate Bio (Translate Bio) Business Description

Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Executives
Jean Francois Formela director C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr director, officer: Chief Executive Officer, other: President C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess officer: Chief Operating Officer, CLO, other: Secretary C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc. 10 percent owner 300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c. 10 percent owner 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma 10 percent owner 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman director C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge director C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch director
Robert J. Meyer director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier officer: Chief Medical Officer 255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109